GlassScriptPhysician profile
Veena Goel
NPI 1124021837
$1,195.11
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $359 · 2020: $306 · 2021: $468 · 2022: $62.09.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $278.58 | 2019-2021 | |
| Lilly USA, LLC | $176.76 | 2019-2021 | |
| Novo Nordisk INC | $154.54 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $106.00 | 2019 | |
| Novartis Pharmaceuticals Corporation | $89.81 | 2019-2020 | |
| Abbott Laboratories | $78.94 | 2021-2022 | |
| Pfizer INC. | $77.71 | 2019-2021 | |
| Astellas Pharma US INC | $64.96 | 2019-2021 | |
| Amarin Pharma, INC. | $61.60 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $58.19 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.37 | 2021 | |
| Amgen INC. | $15.74 | 2019 | |
| Mannkind Corporation | $13.91 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Veena Goel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.